OrganoClick AB (ORGC) AI Stock Analysis

• Market Cap: kr192.51M
• Dividend Yield: N/A
• Average Volume (3M): 87.89K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.20
• Revenue Growth: -18.29%
• EPS Growth: -48.74%
• Country: SE
• Employees: 40
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): -0.10
• Shares Outstanding: 110,003,010
• 10 Day Avg. Volume: 18,569
• 30 Day Avg. Volume: 87,893
• PEG Ratio: -0.05
• Price to Book (P/B): 11.75
• Price to Sales (P/S): 1.68
• P/FCF Ratio: -16.96
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.09
• Revenue Forecast (FY): kr121.00M

• Rating: 42 Neutral
• Price Target: kr1.50 ▼(-15.73% Downside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is primarily weighed down by weak financial performance (recurring losses, negative free cash flow, and sharply higher leverage). Technicals add pressure with a clear downtrend below key moving averages and negative MACD, while valuation is constrained by a negative P/E and no dividend support.

Positive Factors

Sustainable bio-based technology platform

OrganoClick’s core bio-based chemistry platform targets material modification and surface treatment across wood and textile applications. That platform-level IP and product focus create structural differentiation in sustainability-oriented markets and support cross-industry application and collaboration potential over time.

Diversified B2B and B2C revenue channels

The company sells both industrial bio-based formulations to manufacturers and branded consumer products via retail/e-commerce. This dual-channel model provides durable revenue diversification, multiple commercialization routes, and optional licensing/collaboration pathways that can sustain growth as one channel faces cyclicality.

Historical gross margin improvement

Reported improvement in gross margin versus 2022 indicates periods of better cost structures or pricing power. Sustained higher gross margins are the main structural lever to convert revenues into lasting operating profits once volume and fixed-cost absorption stabilize.

Negative Factors

Persistent and worsening losses

The company has been loss-making across reported years with a steep deterioration to ~-34% net margin in 2025 and widening operating losses. Persistent negative profitability erodes retained capital, forces external funding needs, and makes long-term viability dependent on material margin recovery.

Negative operating and free cash flow

Operating cash flow moved negative in 2025 and free cash flow has been negative throughout the reported periods, indicating ongoing cash burn. Weak cash generation limits the company’s ability to self-fund growth, increases reliance on financing, and constrains resilience to shocks.

Sharp rise in leverage and weakened equity base

Leverage increased markedly to ~6.4x debt-to-equity as equity shrank and debt rose, while ROE is deeply negative (~-240%). High leverage amid losses amplifies solvency risk, raises financing costs, and materially reduces strategic and operational flexibility over the medium term.

OrganoClick AB Business Overview & Revenue Model

Company Description

OrganoClick AB (publ), a material and chemical technology company, develops, produces, and markets fiber-based materials and chemicals for treatment of wood, technical textile and nonwoven, and bio composites in Sweden. It offers OrganoWood, a wood preservative technology and wood preservative that gives wood enhanced durability against rot and fire primarily for construction companies and consumers; OrganoTex, a biodegradable durable water repellent technology and textile treatment that makes textile products water repellent, as well as offers shoe and clothes care products; and OrganoComp, a biobased plastic-free and degradable bio-composite used for making 3D-shaped objects that replaces hard plastic materials. The company also provides consumer products, including a range of maintenance and cleaning products for wood, facades, roofs, and terraces, as well as for car care under the BIOkleen name; OC-BioBinder, a biobased, plastic-free, and degradable binder used by industrial customers as a replacement for plastic binders in nonwoven and technical textiles; and OC-AquaSil Tex, a biodegradable hydrophobing product used to replace PFAS in nonwovens, specialty papers, and technical textiles. The company was founded in 2006 and is headquartered in Täby, Sweden.

How the Company Makes Money

OrganoClick generates revenue primarily through the sale of its sustainable products to various industries, including textiles, construction, and packaging. The company has several key revenue streams, including direct sales of its innovative textile solutions, functional coatings, and biocomposite materials. Additionally, OrganoClick engages in partnerships with manufacturers and brands seeking to incorporate sustainable materials into their products, which can lead to collaborative projects and licensing agreements. The company's focus on research and development also allows it to stay competitive and expand its product offerings, contributing to its overall earnings.

OrganoClick AB Financial Statement Overview

Summary

Financials are weak: recurring losses with a sharply worse 2025 net margin (~-34%), negative operating cash flow in 2025, and persistently negative free cash flow. Balance-sheet risk increased meaningfully as leverage rose to ~6.4x debt-to-equity alongside a shrinking equity base, reducing financial flexibility.

Income Statement

Profitability remains weak: the company has been loss-making every year shown, with 2025 net margin deteriorating to about -34% (vs. ~-14% in 2024) and operating losses widening materially. Revenue also contracted in 2024 and again in 2025 after a stronger 2023, signaling an uneven growth profile. A key positive is that gross margin improved versus 2022, but it fell sharply in 2025, underscoring volatility in pricing/cost absorption and limited operating leverage so far.

Balance Sheet

Leverage has increased significantly: debt-to-equity rose to ~6.4x in 2025 from ~1.8x in 2024 as equity declined while debt increased, reducing financial flexibility. Returns on equity are deeply negative (about -240% in 2025), reflecting heavy losses against a thinner equity base. Total assets are relatively stable, but the capital structure has become meaningfully more risk-prone versus prior years.

Cash Flow

Cash generation is pressured: operating cash flow turned negative in 2025 (after being positive in 2024), and free cash flow is negative across all periods provided, worsening in 2025. While free cash flow was sometimes better than reported earnings (helped by non-cash charges/working-capital timing), the overall pattern is continued cash burn, implying reliance on financing and/or improved profitability to stabilize liquidity.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	106.19M	127.23M	145.87M	115.05M	110.06M
Gross Profit	14.86M	31.84M	35.39M	12.94M	18.51M
EBITDA	-12.80M	5.71M	5.95M	-21.19M	-12.92M
Net Income	-36.37M	-17.97M	-15.77M	-41.62M	-31.03M
Balance Sheet
Total Assets	135.22M	126.98M	150.75M	162.86M	188.39M
Cash, Cash Equivalents and Short-Term Investments	2.68M	538.00K	10.74M	15.20M	34.25M
Total Debt	96.72M	51.67M	62.39M	61.68M	53.54M
Total Liabilities	114.81M	89.15M	97.34M	95.30M	80.66M
Stockholders Equity	15.18M	28.98M	44.58M	58.78M	100.33M
Cash Flow
Free Cash Flow	-10.51M	-5.51M	-8.08M	-35.35M	-52.34M
Operating Cash Flow	-8.29M	3.60M	533.00K	-21.22M	-37.69M
Investing Cash Flow	-10.99M	-9.11M	-8.61M	-7.45M	-14.65M
Financing Cash Flow	21.42M	-4.69M	3.60M	9.63M	54.56M

OrganoClick AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ORGC, the sentiment is Neutral. The current price of 1.78 is above the 20-day moving average (MA) of 1.64, above the 50-day MA of 1.69, and below the 200-day MA of 1.80, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.36 is Neutral, neither overbought nor oversold. The STOCH value of 79.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ORGC.

OrganoClick AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
POLYG	49 Neutral	kr237.43M	-10.92	-5.04%	2.89%	7.92%	94.99%
NEXAM	45 Neutral	kr232.66M	-11.21	-7.96%	―	-1.89%	-59.17%
IMPC	44 Neutral	kr153.62M	-2.92	―	―	―	―
XPC	44 Neutral	kr56.04M	-4.15	―	―	―	―
ORGC	42 Neutral	kr192.51M	-4.85	-75.16%	―	-18.29%	-48.74%